Advertisement
Advertisement
KURA
Kura Oncology, Inc.
7.27
USDSponsored
+0.47
+6.91%
Nov 06, 15:59 UTC -5
Closed
After-Market
7.31
+0.04
+0.55%
Kura Oncology, Inc. (KURA) Earnings
KURA Earnings Reports
Positive Surprise Ratio
KURA beat 32 of 43 last estimates.
74%
Next Report
Next Week
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$23.07M
/-$0.83
Implied change from Q2 26 (Revenue/ EPS)
+10.51%
/+7.79%
Implied change from Q3 25 (Revenue/ EPS)
+11.17%
/-2.35%
Kura Oncology, Inc. earnings per share and revenue
On Aug 12, 2026, KURA reported earnings of -0.77 USD per share (EPS) for Q2 26, beating the estimate of -0.89 USD, resulting in a 13.99% surprise. Revenue reached 20.87 million, compared to an expected 21.85 million, with a -4.46% difference. The market reacted with a +1.51% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.83 USD, with revenue projected to reach 23.07 million USD, implying an increase of 7.79% EPS, and increase of 10.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Kura Oncology, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Kura Oncology, Inc. reported EPS of -$0.77, beating estimates by 13.99%, and revenue of $20.87M, -4.46% below expectations.
How did the market react to Kura Oncology, Inc.'s Q2 2026 earnings?
The stock price moved up 1.51%, changed from $9.94 before the earnings release to $10.09 the day after.
When is Kura Oncology, Inc. expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Kura Oncology, Inc.'s next earnings report?
Based on 10
analysts, Kura Oncology, Inc. is expected to report EPS of -$0.83 and revenue of $23.07M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.